Altru client goes through experimental COVID-19 treatment

Altru client goes through experimental COVID-19 treatment


Apr 15 th 2020 – 3pm.


A client at Altru Health System who has checked favorable for COVID-19 is undergoing a speculative treatment for the disease, one of the first trials in the state and nation.


The treatment is called convalescent plasma treatment and involves taking plasma from a patient who has actually totally recovered from the coronavirus and offering it to a client who is presently sick with it. The hope is that antibodies– proteins created by the immune system to combat a virus– from a person who has actually recuperated from COVID-19 might give a boost to an individual battling it.

Doctors are studying how COVID-19 antibodies can benefit the body immune system, though it is not clear how they may work. The concept is that the antibodies could develop a person’s body immune system until they are strong enough to combat the infection by themselves.

” It is our objective constantly to supply our patients with the very best care possible,” wrote Emily Gruber, marketing professional for Altru, in an e-mail to the Herald. “Being on the cutting edge of advancing care throughout a time of unforeseen difficulties is a terrific opportunity for Altru.”

The treatment is being performed by Dr. Sara Nausheen, an infectious illness expert at Altru. Nasheen is the principal investigator for the medical facility, which is participating in the Expanded Access to Convalescent Plasma program (EAP) administered by the Mayo Center.

WDAY logo

The treatment started on Sunday, April 12.

The Food and Drug Administration considers the treatment to be an “investigational product,” to which the client must consent.

The EAP is for clients with major or immediately life-threatening COVID-19, as the need for convalescent plasma is greater than the supply.

The FDA’s site refers to convalescent plasma therapy as “appealing.”

Find Out More


Please enter your comment!
Please enter your name here